CHMP positive decision for Bekemv the first eculizumab biosimilar to treat paroxysmal nocturnal haemoglobinuria. - Amgen
Amgen has received a positive opinion from the EMA’s CHMP recommending that its Bekemv eculizumab biosimilar become the first Soliris rival to be granted a pan-European marketing authorization and intended for the treatment of adults and children in paroxysmal nocturnal haemoglobinuria (PNH).
Bekemv is a biosimilar medicinal product. It is highly similar to the reference product Soliris (eculizumab), which was authorised in the EU on 20 June 2007. Data show that Bekemv has comparable quality, safety and efficacy to Soliris.
In August 2020 Alexion Pharmaceuticals reached a patent settlement with Amgen over Soliris (eculizumab), Alexion’s antibody treatment for the blood disease PNH. The agreement prevents Amgen’s biosimilar version of Soliris from entering the US market until 2025.
Related news and insights
Amgen announced new research examining the use of Otezla (apremilast) in psoriatic arthritis, including the Phase IV MOSAIC study and an exploratory analysis of cardiometabolic risk factors, which are commonly elevated in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy
Akebia Therapeutics, Inc. announced that the company received a written response from the Office of New Drugs (OND) of the FDA to Akebia's Formal Dispute Resolution Request (FDRR) regarding the Complete Response Letter (CRL) received in March 2022 for vadadustat
UCB, a global biopharmaceutical company, announced new long-term 52-week data from three Phase III studies BE COMPLETE with its long-term extension study, BE MOBILE 1 and BE MOBILE 2 – evaluating the efficacy and safety profile of bimekizumab, an inhibitor of IL-17F in addition to IL-17A, in adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) and active ankylosing spondylitis (AS), also known as radiographic axSpA (r-axSpA), respectively